KZR stock exits Nasdaq after Aurinia merger closes
Published on 10/04/2026 at 12:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
KZR stock exited its standalone Nasdaq story after Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences on May 11, 2026. The transaction delivered USD 6.955 in cash per share plus one contingent value right, turning the former clinical-stage biotech into a wholly owned Aurinia subsidiary.
Cash deal closes at USD 6.955
According to StockTitan in the May 11, 2026 filing, 5,927,580 shares were validly tendered, representing 80.24 percent of the outstanding shares. The follow-on merger then made Kezar a wholly owned subsidiary of Aurinia under Section 251(h) of Delaware law.
The consideration also included one non-transferable contingent value right for each Kezar share. The CVR could provide additional cash tied to Kezar's remaining net cash, legacy agreements and future development or monetization of zetomipzomib.
Trading status changes the investment case
StockTitan reports that trading in KZR common stock was suspended and that the company was delisted from Nasdaq after the merger. By October 4, 2026, the relevant shareholder outcome was therefore the completed cash-and-CVR transaction, not a continuing standalone equity listing.
The operating figures explain why the deal mattered for Kezar's remaining assets. In Q1 2026, Kezar posted a net loss of USD 5.8 million, compared with USD 16.6 million a year earlier, while research and development spending fell to USD 1.5 million after trial terminations and a 70 percent workforce reduction, according to StockTitan.
Cash supported the transaction
Kezar held USD 66.2 million in cash and cash equivalents as of March 31, 2026, and management said that liquidity could fund operations for at least 12 months. That cash position provided a concrete counterweight to the USD 5.8 million quarterly loss, while the CVR preserved potential value from legacy programs.
KZR stock becomes a completed deal
The May 11, 2026 merger price of USD 6.955 per share and the 80.24 percent tender rate define the completed KZR shareholder outcome. The remaining value depends on the contingent value right and Aurinia's handling of Kezar's retained assets.
Kezar Life Sciences stock details
- Company: Kezar Life Sciences, Inc.
- Ticker: KZR
- Trading venue: Nasdaq
- Sector / Industry: Healthcare / Biotechnology
